RepID orchestrates CDH1 and CTNNB1 homeostasis to regulate metastatic potential in small cell lung cancer.
These findings establish RepID as a previously unrecognized molecular rheostat that constrains SCLC metastatic potential by integrating transcriptional regulation of epithelial integrity with post-translational control of the CRL1-CTNNB1 axis, providing a potential therapeutic vulnerability in recalcitrant SCLC.